Pharmaceutical Drugs Coverage

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Definition And Segments

Attention deficit hyperactivity disorder (ADHD) therapeutics refers to the range of treatments and interventions aimed at managing the symptoms and improving the functioning of individuals diagnosed with ADHD. ADHD is a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity that significantly interfere with daily functioning and development. The primary objective of ADHD therapeutics is to enhance attention, impulse control, and overall functioning in daily activities, thereby improving the quality of life for individuals affected by ADHD. The main types of drugs in attention deficit hyperactivity disorder (ADHD) therapeutics are stimulants and non-stimulants. Stimulants are medications that increase certain chemicals in the brain, helping improve attention and focus. It includes various psychotherapies, such as behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy, and is adapted for different age groups, including pediatric, adolescent, and adult, and distributed through hospital pharmacies, specialty clinics, retail pharmacies, and e-commerce. The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented – 1) By Drug Type: Stimulants, Non-Stimulants 2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy 3) By Age Group: Pediatric And Adolescent, Adult 4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce The attention deficit hyperactivity disorder (ADHD) therapeutics market size has grown strongly in recent years. It will grow from $12.37 billion in 2023 to $13.21 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to diagnostic awareness and screening programs, rising incidence of ADHD, advancements in treatment modalities, healthcare infrastructure development, and health insurance coverage expansion. The attention deficit hyperactivity disorder (ADHD) therapeutics market size is expected to see strong growth in the next few years. It will grow to $16.42 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to genetic research and personalized medicine, increasing mental health awareness, global and national mental health initiatives, telehealth expansion, integration of behavioral therapies. Major trends in the forecast period include technological innovations in treatment, research and development initiatives, digital therapeutics integration, precision medicine approaches, innovations in drug delivery systems.

Rising Prevalence Of ADHD Spurs Growth In The Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutic Market

The increasing prevalence of attention-deficit hyperactivity disorder is expected to propel the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutics market going forward. The rising prevalence of attention-deficit hyperactivity disorder (ADHD) refers to the growing number of individuals diagnosed with this neurodevelopmental disorder over time. ADHS therapeutics address the multifaceted nature of the condition, aiming to improve symptom management, functional impairment, quality of life, and overall well-being for individuals affected by ADHD. For instance, in January 2023, according to reports published by the Guardian, a US-based news publishing company, an estimated 170,000 identified patients were prescribed for ADHD in 2022, a 20.4% increase from the 141,000 identified patients during the same period in 2021. Therefore, the increasing prevalence of ADHD is driving the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutic market. Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical's, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.

Leading Companies Innovate With Over-The-Counter (OTC) Digital Therapeutics For ADHD In The US Market

Major companies operating in the attention-deficit hyperactivity disorder (ADHD) therapeutics market are focusing on the development of digital advancements such as Endeavor over-the-counter (OTC) versions of digital therapeutics for ADHD to meet increased demand for digital solutions and the rise in demand for remote healthcare. Digital therapeutics are evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. These interventions are designed to be used independently or with traditional medical treatments. For instance, in June 2023, Akili, a US-based digital health company, launched an over-the-counter (OTC) version of its video game-based digital therapeutic for adults with attention-deficit hyperactivity disorder (ADHD). The OTC version, EndeavorOTC, is designed to improve attention, time management, and organizational skills. Additionally, this move follows the success of Akili's FDA-authorized prescription video game treatment, EndeavorRx, for children with ADHD. The OTC version provides adults with a non-drug treatment option for managing ADHD symptoms.

Optum Inc. Strengthens Behavioral Health Services With Acquisition Of Refresh Mental Health

In March 2022, Optum Inc., a US-based healthcare services provider company, acquired Refresh Mental Health for $700 million. This acquisition will enhance Optum's outpatient mental and behavioral health service provider position. It will expand its effective behavioral care to patients and drive deeper medical and behavioral health care integration. Refresh Mental Health is a US-based company offering various mental and behavioral health services, including ADHD psychiatry and therapy. North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The attention deficit hyperactivity disorder (ADHD) therapeutic market consists of revenues earned by entities by providing services such as medication management, behavioral therapy, social skills training, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The attention deficit hyperactivity disorder (ADHD) therapeutic market also includes sales of medication, behavioral modification tools, organization and planning tools, and assistive technologies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The attention deficit hyperactivity disorder (ADHD) therapeutics market research report is one of a series of new reports from The Business Research Company that provides attention deficit hyperactivity disorder (ADHD) therapeutics market statistics, including attention deficit hyperactivity disorder (ADHD) therapeutics industry global market size, regional shares, competitors with a attention deficit hyperactivity disorder (ADHD) therapeutics market share, detailed attention deficit hyperactivity disorder (ADHD) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the attention deficit hyperactivity disorder (ADHD) therapeutics industry. This attention deficit hyperactivity disorder (ADHD) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biologics CDMO Market Definition And Segments

A biologics contract development and manufacturing organization (CDMO) is a service provider that supports pharmaceutical companies in the development and production of biologic drugs, which include vaccines, blood and blood components, allergens, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. The main cell types in biologics CDMO are mammalian and non-mammalian. Mammalian refers to cell lines derived from mammals, commonly used in the production of biologics and cell-based therapies due to their ability to produce complex proteins and maintain post-translational modifications. The various products types include biologics and biosimilars. The biologics CDMO market covered in this report is segmented – 1) By Cell Type: Mammalian, Non-Mammalian 2) By Product Type: Biologics, Biosimilars The biologics CDMO market size has grown rapidly in recent years. It will grow from $18.44 billion in 2023 to $21.30 billion in 2024 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to rise in biologics development, cost efficiency and flexibility, focus on core competencies, regulatory compliance and quality assurance, globalization of pharmaceutical supply chains. The biologics CDMO market size is expected to see rapid growth in the next few years. It will grow to $36.54 billion in 2028 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to increasing demand for biologic therapies, emergence of biosimilars and biobetters, investments in biomanufacturing infrastructure, shift towards outsourcing complex processes, focus on supply chain resilience and risk mitigation, regulatory harmonization, and expedited approvals. Major trends in the forecast period include expansion of capabilities to offer end-to-end solutions, adoption of single-use technologies, integration of continuous manufacturing processes, emergence of specialized CDMOs.

Rise In Demand For Cell And Genetic Therapy Fuels Biologics CDMO Market Growth

The surge in demand for cell and genetic therapy is expected to propel the growth of the biologic CDMO market going forward. Cell and gene therapy are innovative medical approaches that utilize living cells or genetic material to address underlying disease causes at the cellular or genetic level, providing potential treatments for conditions that are difficult to manage or incurable with traditional pharmaceuticals. The demand for cell and gene therapy is rising due to their potential to offer innovative treatments for diseases by addressing underlying genetic or cellular causes. Biologic CDMOs provide expertise in handling living cells, viral vectors, and genetic material, facilitating safe and efficient production of cell and gene therapies while assisting biopharmaceutical companies in navigating regulatory requirements and technical challenges, thereby facilitating translation from research to clinical application. For instance, in January 2023, according to The American Society of Gene & Cell Therapy (ASGCT), a US-based primary professional membership organization, the gene, cell, and RNA therapy pipeline saw 7% growth in 2022, reaching a total of 3,726 therapies in development. Of these, 55% are gene therapies, while 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Therefore, the surge in demand for cell and genetic therapy is driving the growth of the biologic CDMO market. Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

Advancements In Biologics CDMO

Major companies operating in the biologics CDMO market are developing technologically advanced solutions, such as new cell lines, to enhance biopharmaceutical development and manufacturing efficiency and capabilities. The technology produces therapeutic antibodies with enhanced potency, addressing immunotherapy research and development challenges. For instance, in November 2023, Lonza Group, a Switzerland-based manufacturing company that specializes in the pharmaceutical and biotechnology sectors, launched GS Effex cell lines, designed to produce antibodies that are 100% free of fucose, a sugar molecule and demonstrate increased potency without compromising on other performance attributes. It helps overcome immunotherapy research and development challenges related to the need for antibody therapeutics to increase potency. It is a stable, scalable, and productive cell line that provides a solution for therapeutic development from discovery-stage research through commercial manufacturing.

Bora Pharmaceuticals Expands Global Footprint With Acquisition Of Eden Biologics Inc.

In May 2022, Bora Pharmaceuticals Co. Ltd., a Taiwan-based organization that specializes in manufacturing and selling pharmaceutical products, acquired the CDMO assets of Eden Biologics Inc. for $100 million. The aim of the acquisition is to expand its presence in the global CDMO market, particularly focusing on biologics, macromolecules, and cell and gene therapy markets. Eden Biologics Inc. is a Taiwan-based biotechnology company specializing in the contract development and manufacturing of innovative biologics for therapeutic applications. North America was the largest region in the biologics CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics CDMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The biologics CDMO market consist of revenues earned by entities by providing services such as process development, analytical development, cell line development, supply chain management, and fill-finish services. The biologics CDMO market also includes sales of monoclonal antibodies, recombinant proteins, antisense and molecular therapy, and vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biologics CDMO research report is one of a series of new reports from The Business Research Company that provides biologics CDMO market statistics, including the biologics CDMO industry's global market size, regional shares, competitors with an biologics CDMO market share, detailed biologics CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the biologics CDMO industry. This biologics CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

High Throughput Screening (HTS) Market Definition And Segments

High-throughput screening (HTS) is a technique employed in drug discovery and various scientific domains to rapidly assess a large number of samples for biological activity. Its purpose is to identify active compounds, antibodies, or genes that modulate specific biological pathways, thereby expediting the drug discovery process. The main types of products and services in high-throughput screening (HTS) are consumables and reagents, instruments, software, and services. Consumables and reagents refer to the materials and chemicals used in the screening process, including sample containers, assay reagents, and other disposable items necessary for experimental procedures. The technology types are categorized into ultra-high-throughput screening, cell-based assays, lab-on-a-chip, and label-free technology, which are used in several applications such as target identification and validation, primary and secondary screening, toxicology assessment, and others. The end users include the pharmaceutical and biotechnology industries, academic and research institutes, contract research organizations, and others. The high throughput screening (HTS) market covered in this report is segmented – 1) By Products And Services: Consumables And Reagents, Instruments, Software And Services 2) By Technology: Ultra-High-Throughput Screening, Cell-Based Assays, Lab-on-a-chip, Label-Free Technology 3) By Application: Target Identification And Validation, Primary And Secondary Screening, Toxicology Assessment, Other Applications 4) By End User: Pharmaceuticals And Biotechnology Industry, Academics And Research Institute, Contract Research Organization, Other End Users The high throughput screening market size has grown rapidly in recent years. It will grow from $20.66 billion in 2023 to $22.98 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing adoption of high-throughput screening, rising r&d spending, growing availability of funds for research, increasing healthcare spending, competitive market landscape. The high throughput screening market size is expected to see strong growth in the next few years. It will grow to $33.1 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing market size and growth rate, strategic developments by key players, rising demand for disease monitoring and drug discovery, rising prevalence of chronic diseases, growing focus towards implementation of ultra high throughput screening (UHTS) techniques. Major trends in the forecast period include technological advancements in high-throughput screening, growing focus towards implementation of ultra high throughput screening (UHTS) techniques.

Impact Of Chronic Disease Prevalence On High Throughput Screening (HTS) Market Growth

The rise in the prevalence of chronic diseases is expected to propel the growth of the high-throughput screening (HTS) market going forward. Chronic disease refers to a long-term health condition or disease that persists over an extended period, typically lasting for three months or more. HTS enables rapid screening of numerous chemical compounds to pinpoint potential drug candidates targeting specific pathways or mechanisms implicated in chronic diseases, essential for their effective long-term management For instance, in January 2023, according to a report published by the National Library of Medicine, a US-based medical library run by the federal government, the number of people aged 50 and older with one or more chronic diseases is expected to increase by 99.5%, totaling 142.66 million by 2050, compared to 71.522 million in 2020 in the United States of America. Therefore, the rise in the prevalence of chronic diseases will drive the growth of the high-throughput screening (HTS) market. Major companies operating in the high throughput screening (HTS) market are Thermo Fisher Scientific Inc., AstraZeneca Plc, Danaher Corporation, Merck Group, GE HealthCare Technologies Inc., Corning Inc., Agilent Technologies Inc., Lonza Group Ltd., Charles River Laboratories International Inc, Beckman Coulter Inc., PerkinElmer Inc., Bio-Rad Laboratories, Tecan Group Ltd., Sygnature Discovery Ltd., Luminex Corporation, Hamilton Company, Crown Bioscience Inc., HighRes Biosolutions, NanoTemper Technologies GmbH, BMG LABTECH GmbH, Axxam SpA, Reprocell Inc., BioTek Instruments Inc, Aurora Biomed Inc., Cyclica Inc., Biomat Srl, Diana Biotechnologies s.r.o

Innovative Multimode Plate Reader Revolutionizes High Throughput Screening Market

Major companies operating in the high-throughput screening market are developing innovative products, such as multimode plate readers, to better serve their customers with advanced features. A multimode plate reader (MPR) is an advanced lab tool used in high-throughput screening, analyzing biological and chemical samples in microplates by integrating multiple detection modes for diverse assays within a single platform. For instance, in February 2023, PerkinElmer Inc., a US-based MedTech company, launched the EnVision Nexus system. The EnVision Nexus system stands out as the fastest and most sensitive multimode plate reader available, explicitly designed for demanding high-throughput screening (HTS) applications to expedite drug discovery efforts. With its unique technology, including dual detectors and optimized reagents like proprietary HTRF and AlphaLISA, coupled with the latest reagent kits, the platform offers researchers unparalleled assay flexibility, accuracy, speed, and sensitivity. Equipped with walkaway convenience options such as a plate stacker for 20 or 50 plates or full automation and integration for continuous 24/7 workflow-driven operations, the EnVision Nexus system empowers researchers to efficiently screen millions of samples with unprecedented efficiency.

PerkinElmer Inc. Expands Life Sciences Portfolio With Acquisition Of Covaris Inc.

In December 2023, PerkinElmer Inc., a US-based MedTech company, acquired Covaris Inc. for an undisclosed amount. With this acquisition, Covaris' growth potential is anticipated to be accelerated, while PerkinElmer's existing life sciences portfolio is poised to expand into the rapidly growing diagnostics end market. Covaris Inc. is a US-based provider of high-throughput screening solutions. North America was the largest region in the high throughput screening market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the high throughput screening (HTS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the high throughput screening (HTS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The high-throughput screening (HTS) market consists of revenues earned by entities by providing services such as compound library screening, assay design and adaptation, and pilot screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The high-throughput screening (HTS) market also includes sales of lab equipment and supplies, chemicals, assay development tools, and data processing software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The high throughput screening (HTS) research report is one of a series of new reports from The Business Research Company that provides high throughput screening (HTS) market statistics, including the high throughput screening (HTS) industry's global market size, regional shares, competitors with an High throughput screening (HTS) market share, detailed high throughput screening (HTS) market segments, market trends and opportunities, and any further data you may need to thrive in the high throughput screening (HTS) industry. This high throughput screening (HTS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Artificial Intelligence (AI) In Biopharmaceuticals Market Definition And Segments

Artificial intelligence (AI) in biopharmaceuticals refers to applying various AI techniques to analyze complex biological data and improve various aspects of drug discovery, development, and delivery within the pharmaceutical industry. AI in biopharmaceuticals holds great promise for revolutionizing drug discovery, development, and delivery processes by accelerating timelines, reducing costs, and improving the efficiency and effectiveness of treatments. The main types of offerings in artificial intelligence (AI) in biopharmaceuticals are hardware, software, and services. Hardware refers to the physical components of a computer system, including devices such as memory, disk drives, controllers, and specialized software like database management systems. It includes various deployments, including cloud and on-premises, and the technologies used are machine learning, natural language processing, and deep learning, as well as applications used in business processes and supply chains, drug discovery, medical imaging and diagnostics, and precision medicine, end users are manufacturers, contract research organizations, and academic and government research institutes. The artificial intelligence (AI) in biopharmaceuticals market covered in this report is segmented – 1) By Offering: Hardware, Software, Services 2) By Deployment: Cloud, On-Premises 3) By Technology: Machine Learning, Natural Language Processing, Deep Learning, Other Technologies 4) By Application: Business Process And Supply Chain, Drug Discovery, Medical Imaging And Diagnostics, Precision Medicine 5) By End-Users: Manufacturers, Contract Research Organizations, Academic And Government Research Institutes The artificial intelligence (AI) in biopharmaceuticals market size has grown exponentially in recent years. It will grow from $1.19 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 33.8%. The growth in the historic period can be attributed to advancements in computational power, biomedical data explosion, precision medicine paradigm, regulatory support and guidance. The artificial intelligence (AI) in biopharmaceuticals market size is expected to see exponential growth in the next few years. It will grow to $4.99 billion in 2028 at a compound annual growth rate (CAGR) of 33.1%. The growth in the forecast period can be attributed to advancements in computational biology, integration of multi-modal data, convergence of ai and life sciences, regulatory support and frameworks, ethical and fair ai principles. Major trends in the forecast period include integration of multi-omics data, AI-driven drug design and discovery, explainable AI and regulatory acceptance, technological advancements, regulatory developments, and emerging opportunities.

Chronic Disease Prevalence Fueling Growth Of AI In Biopharmaceuticals Market

The growing prevalence of chronic diseases is expected to propel the growth of artificial intelligence (AI) in biopharmaceuticals market going forward. Chronic diseases are long-lasting conditions that generally progress slowly and may persist for years or even a lifetime. It arises from lifestyle factors, an aging population, genetic predispositions, and environmental factors. AI in biopharmaceuticals is increasingly used to manage chronic diseases because it analyzes large volumes of diverse data sources, identifies patterns, and personalizes treatment approaches. For instance, according to the National Library of Medicine, a US-based medical library, chronic diseases are expected to grow by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Therefore, the growing prevalence of chronic diseases drives the growth of artificial intelligence (AI) in the biopharmaceuticals market. Major companies operating in the artificial intelligence (AI) in biopharmaceuticals market are Apple Inc., Google LLC, Microsoft Corporation, Tencent Holdings Limited, Amazon Web Services Inc., International Business Machines Corporation, Exscientia Limited, NVIDIA Corporation, Amgen Inc., DeepMind Technologies Limited, Schrödinger Inc., XtalPi Inc., ConcertAI Inc., Insilico Medicine Inc., Recursion Pharmaceuticals, BenevolentAI, BioXcel Therapeutics, Atomwise Inc., BioAge Labs Inc., GNS Healthcare, Berg Health, Deep 6 AI Inc., Cloud Pharmaceuticals Inc., Numerate Inc., AI Therapeutics, Envisagenics, twoXAR Inc., Cyclica Inc.

Advancements In AI-Powered Solutions For Drug Discovery And Precision Medicine

Major companies operating in artificial intelligence (AI) in biopharmaceuticals focus on developing innovative advancements such as target and lead identification suite AI-powered solutions to accelerate drug discovery and precision medicine to transform life sciences organizations. These solutions for drug discovery and precision medicine encompass a variety of innovative approaches to developing new drugs and tailoring treatments to individual patients. For instance, in May 2023, Google LLC, a US-based provider of cloud computing services, launched two new AI-powered tools called target and lead identification suites, designed to help researchers predict and understand the structure of proteins, which is a fundamental part of drug development. Additionally, this suite will help researchers ingest, store, analyze, and share mass amounts of genomic data, which is crucial for precision medicine. Also, these tools aim to streamline the drug discovery process, reduce costs, and bring new treatments to market faster. By providing efficient data management, accurate predictions of protein structures, and advanced genomic analysis capabilities, these tools aim to revolutionize drug development processes and improve patient outcomes.

ZS Associates' Acquisition Of Trials.ai Inc. To Revolutionize Clinical Trial Design with AI

In February 2023, ZS Associates, a US-based management consulting and technology firm, acquired Trials.ai Inc. for an undisclosed amount. With this acquisition, Associates aims to enhance design processes within the pharmaceutical industry by leveraging artificial intelligence (AI) to optimize speed, improve participant experiences, and expedite the delivery of pharmaceutical therapies to the market. Trials.ai Inc. is a US-based company that focuses on revolutionizing clinical trials through artificial intelligence (AI) and machine learning (ML) technologies. North America was the largest region in the artificial intelligence (AI) in biopharmaceuticals market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in biopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) in biopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The artificial intelligence (AI) in biopharmaceuticals market consists of revenues earned by entities by services such as drug discovery, personalized medicine analytics, clinical trial optimization, healthcare decision support, and data integration and analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) in biopharmaceuticals market also includes of sales of decision support System, predictive modeling tools, robotics, and automation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The artificial intelligence (AI) in biopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) in biopharmaceuticals market statistics, including artificial intelligence (AI) in biopharmaceuticals industry global market size, regional shares, competitors with an artificial intelligence (AI) in biopharmaceuticals market share, detailed artificial intelligence (AI) in biopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in biopharmaceuticals industry. This artificial intelligence (AI) in biopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial Intelligence (AI) In Predictive Toxicology Market Definition And Segments

Artificial intelligence (AI) in predictive toxicology refers to the use of artificial intelligence techniques to analyze biological, chemical, and environmental data to predict the potential toxicity of chemicals and compounds. It is used to expedite chemical safety assessments, predict drug toxicity, and prioritize chemicals for further testing. The main components of artificial intelligence (AI) in predictive toxicology include solutions and services. Solutions refer to software platforms or systems designed to analyze data and predict toxicological outcomes and also utilize advanced algorithms and models to assess the potential risks of chemical compounds, offering comprehensive tools for toxicity prediction and risk assessment and aiding in drug development and chemical safety evaluation. It includes several types of technologies, such as machine learning, natural language processing, computer vision, and others, which are used in several toxicity endpoint applications, including genotoxicity, hepatotoxicity, neurotoxicity, cardiotoxicity, and others. These are used by various end users, such as pharmaceutical and biotechnology companies, chemical and cosmetics companies, contract research organizations, and others. The artificial intelligence (AI) in predictive toxicology market covered in this report is segmented – 1) By Component: Solution, Services 2) By Technology: Machine Learning, Natural Language Processing, Computer Vision, Other Technologies 3) By Toxicity Endpoints: Genotoxicity, Hepatotoxicity, Neurotoxicity, Cardiotoxicity, Other Toxicity Endpoints 4) By End User: Pharmaceutical And Biotechnology Companies, Chemical And Cosmetics, Contract Research Organizations, Other End Users The artificial intelligence (AI) in predictive toxicology market size has grown exponentially in recent years. It will grow from $0.38 billion in 2023 to $0.50 billion in 2024 at a compound annual growth rate (CAGR) of 30.3%. The growth in the historic period can be attributed to increasing regulatory pressure for toxicity assessment, growing concerns about chemical safety, availability of large datasets for model training, rising costs and ethical concerns associated with animal testing, demand for faster and more cost-effective toxicity screening methods. The artificial intelligence (AI) in predictive toxicology market size is expected to see exponential growth in the next few years. It will grow to $1.41 billion in 2028 at a compound annual growth rate (CAGR) of 29.9%. The growth in the forecast period can be attributed to emergence of explainable artificial intelligence (AI) in toxicology predictions, demand for personalized toxicity assessments, regulatory acceptance and standardization of AI-based toxicity predictions, rise in predictive toxicology outsourcing services, expansion of AI applications in drug discovery and development. Major trends in the forecast period include shift towards 3D cell culture models for toxicity testing, rise of federated learning approaches for collaborative toxicity prediction, application of generative models for predicting chemical toxicity pathways, incorporation of natural language processing for extracting toxicity data from literature, growth of virtual screening platforms for prioritizing chemical testing.

Increasing Demand For Efficient And Ethical Drug Discovery Processes Driving AI In Predictive Toxicology Market Growth

The increasing demand for efficient and ethical drug discovery processes is expected to propel the growth of artificial intelligence (AI) in predictive toxicology market going forward. Drug discovery is an intricate and dynamic process that involves the systematic exploration, synthesis, and evaluation of chemical compounds to discover potential therapeutic agents to alleviate diseases and enhance overall well-being, while efficient and ethical drug discovery processes involve leveraging advanced technologies and prioritizing responsible research practices to develop new therapeutic agents. The demand for efficient and ethical drug discovery processes is driven by rising chronic diseases, growing trend towards personalized medicine, and an increased prevalence of age-related diseases. Artificial intelligence (AI) in predictive toxicology enhances drug discovery processes by efficiently analyzing vast datasets to predict potential toxicological outcomes, thereby accelerating drug development while ensuring ethical standards are met. For instance, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry, the total pharmaceutical R&D expenditure in Europe accounted for $49,500 million (€44,500 million) in 2022, an increase of approximately 6.45% from $46,500 million (€42,533 million) in 2021. Therefore, the increasing demand for efficient and ethical drug discovery processes is driving the growth of the artificial intelligence (AI) in predictive toxicology market. Major companies operating in the artificial intelligence (AI) in predictive toxicology market are Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, Wuxi AppTec, Charles River Laboratories International, Medidata Solutions Inc., Certara Inc., Schrödinger, Merative L.P., Molecular Devices LLC, Envigo (Inotiv Inc.), Instem plc, Simulations Plus, Cyprotex, Recursion Pharmaceuticals, Exscientia PLC, BIOVIA Corporation, Lhasa Limited, Chemaxon Ltd., Insilico Medicine Inc., Algorithme Pharma, CiToxLAB, ArisGlobal, Benevolent AI, Berg Health, Cyclica Therapeutics Inc., Celsius Therapeutics, Biovista Inc., BioTeam Inc.

Key Players Driving Innovation Through Strategic Collaborations In The Pharmaceutical Industry

Major companies operating in the artificial intelligence (AI) predictive toxicology market are adopting a strategic collaboration approaches to enhance market presence and innovation. These collaborations aim to leverage AI and machine learning techniques to improve the prediction and assessment of the toxicity of chemical compounds and pharmaceuticals. For instance, in January 2024, SyntheticGestalt, a UK-based AI research and development company offering AI drug discovery solutions, partnered with Enamine, a Ukraine-based provider of chemical building blocks, screening compounds, and integrated drug discovery services, to develop a set of AI models facilitating the generation of synthetically accessible biologically active compounds, optimizing their physicochemical and ADME or Tox (Absorption, Distribution, Metabolism, and Excretion or Toxicity) properties. These models will find application in SyntheticGestalt's compound discovery endeavors, catering to both academic users and pharmaceutical companies through their services. Enamine has made its extensive Enamine REAL database, containing 38 billion molecules, available for access. SyntheticGestalt will integrate this database into its Drug Discovery Service, utilizing proprietary AI models to predict the physicochemical and ADME or Tox properties of compounds. The service will promptly suggest improved alternative compounds for those with issues.

Strategic Acquisition Amplifies Portfolio And Position In Predictive Toxicology Market

In August 2021, Clarivate, a UK-based company that provides insights and analytics services acquired Bioinfogate for an undisclosed amount. This acquisition enhances Clarivate's portfolio with the OFF-X portal, leading to improved drug toxicity data, streamlined processes, and a strengthened position in the life sciences sector, signifying a significant advancement in meeting the growing demand for artificial intelligence in predictive toxicology solutions. Bioinfogate is a Spain-based company that is engaged in developing predictive and AI models for drug discovery, focusing on toxicity and safety aspects. North America was the largest region in the artificial intelligence (AI) in predictive toxicology market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in predictive toxicology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) in predictive toxicology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Artificial intelligence (AI) in predictive toxicology market includes revenues earned by entities by providing services such as toxicity prediction modeling, risk assessment, chemical prioritization, and toxicity data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The artificial intelligence (AI) in predictive toxicology research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) in predictive toxicology market statistics, including the artificial intelligence (AI) in predictive toxicology industry's global market size, regional shares, competitors with an artificial intelligence (AI) in predictive toxicology market share, detailed artificial intelligence (AI) in predictive toxicology market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in predictive toxicology industry. This artificial intelligence (AI) in predictive toxicology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

HERG Screening Market Definition And Segments

Human Ether-à-go-go-related gene (HERG) screening refers to the process of assessing the potential cardiotoxicity of a drug or compound. HERG screening is an important component of preclinical safety assessment in drug discovery and development, ensuring the safety and efficacy of novel therapeutic agents. The main types of HERG screening are gene KCNH2 and mutant KCNH2. The gene KCNH2, also known as the human ether-à-go-go-related gene hERG gene (hERG), encodes the alpha subunit of a potassium ion channel that plays a crucial role in regulating the electrical activity of the heart. It includes various ion channels, such as voltage-gated and ligand-gated, and is used in several applications, such as antiarrhythmics, antipsychotics, antibiotics, and others. The HERG screening market covered in this report is segmented – 1) By Type: Gene KCNH2, Mutant KCNH2 2) By Ion Channel: Voltage-Gated, Ligand Gated 3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications The HERG screening market size has grown rapidly in recent years. It will grow from $1.42 billion in 2023 to $1.62 billion in 2024 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to increasing drug development activities, regulatory requirements, increasing awareness of cardiac safety, rising incidence of cardiac disorders. The HERG screening market size is expected to see rapid growth in the next few years. It will grow to $2.60 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to expansion of personalized medicine, increasing outsourcing of drug development activities, emerging markets and research, focus on non-cardiac safety assessments. Major trends in the forecast period include advanced in vitro models, integration of genomic and proteomic data, advancements in computational approaches, focus on pediatric drug safety, collaborations for data sharing and standardization.

Expanding HERG Screening Market Fueled By Increasing Prevalence Of Heart Disorders

The rise in the number of patients with heart disorders is expected to propel the growth of the HERG screening market going forward. Heart disorders, also known as cardiovascular disorders or diseases, refer to a range of conditions that affect the heart and blood vessels. These conditions can impact the heart's ability to function properly and may lead to serious health complications. These disorders arise because of unhealthy lifestyles, an aging population, genetic factors, diabetes, and metabolic syndrome. HERG screening helps to identify potential drug candidates, prevent adverse cardiac events that could induce life-threatening cardiac arrhythmias, particularly torsade de pointes (TdP), and improve patient outcomes. For instance, in May 2023, the Centers for Disease Control and Prevention., a US-based national public health agency, reported that in the US, 1 in 20 adults age 20 and older have cardiovascular diseases, 695,000 people were suffering from cardiovascular diseases in 2021, and 375,476 people died with cardiovascular diseases that same year. Furthermore, in March 2022, according to a report published by the Office for National Statistics, a UK-based government department, 19,440 people died of heart attacks in 2020, and this number increased to 20,061 in 2021. Therefore, the rise in the number of patients with heart disorders is driving the growth of the HERG screening market. Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B'SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.

Metrion Biosciences Ltd. Introduces GLP-Certified hERG Screening Service For Enhanced Cardiac Safety In Drug Development

Major companies operating in the HERG screening market are concentrating on new innovative advanced solutions, such as GLP-certified HERG screening services, to enhance cardiac safety assessments during drug development processes. This service refers to the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) using the conventional whole-cell patch-clamp technique. It ensures that the screening is conducted in compliance with regulatory guidelines such as ICH S7A and ICH S7B, which are essential for safety pharmacology studies in drug development. For instance, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, launched the good laboratory practice (GLP)-certified hERG screening service. This service aims to enhance Metrion's support for small-molecule therapeutic development and complement the company's existing cardiac safety service portfolio. Additionally, this service utilizes the conventional whole-cell patch-clamp technique to assess potential cardiac liabilities before entering Phase 1 clinical trials in humans, provides regulatory guidance for safety pharmacology studies in drug development, and offers clients high-quality biology services for ion channel targets.

ApconiX And PhysioStim Establish European Center Of Excellence For Preclinical Cardiovascular Safety Evaluation

In September 2021, ApconiX, a UK-based company specializing in providing fast and efficient HERG screening for drug discovery projects, partnered with PhysioStim. The collaboration aims to establish a European Center of Excellence for preclinical cardiovascular safety evaluation and to provide a comprehensive variety of preclinical cardiac safety tests, including automated electrophysiology for hERG screening, CiPA ion channel assays, and GLP compliance assays. PhysioStim is a France-based preclinical contract research organization specializing in cardiac safety and cardiovascular studies. North America was the largest region in the HERG screening market in 2023. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the HERG screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The HERG screening market includes revenues earned by entities by providing services such as in vitro HERG assays, patch clamp electrophysiology, data analysis and interpretation, consultation and regulatory support, and customized assay development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The HERG screening market research report is one of a series of new reports from The Business Research Company that provides HERG screening market statistics, including HERG screening industry global market size, regional shares, competitors with a HERG screening market share, detailed HERG screening market segments, market trends and opportunities, and any further data you may need to thrive in the HERG screening industry. This HERG screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lab Automation In Drug Discovery Market Definition And Segments

Lab automation in drug discovery refers to the use of advanced technologies and robotics to streamline and optimize laboratory processes related to new drug development and research. It is used to significantly enhance the speed and success rate of drug discovery efforts by automating repetitive tasks and integrating advanced instruments and software. The main types of lab automation in drug discovery are automated liquid handlers, automated plate handlers, robotic arms, automated storage and retrieval systems, and others. Automated liquid handlers are machines designed to dispense and handle liquids automatically, and they are often used in laboratories for precise and efficient liquid handling tasks such as pipetting and dilution. The various components include instruments, software, and services, which are used in several applications, such as high-throughput screening, compound management, sample preparation, and others. These are used by various end-users, including biotechnology and pharmaceutical industries, research institutes, and others. The lab automation in drug discovery market covered in this report is segmented – 1) By Type: Automated Liquid Handlers, Automated Plate Handlers, Robotic Arms, Automated Storage And Retrieval Systems, Other Types 2) By Component: Instruments, Software, Services 3) By Application: High-Throughput Screening, Compound Management, Sample Preparation, Other Applications 4) By End-User: Biotechnology And Pharmaceutical Industries, Research Institutes, Other End-Users The lab automation in drug discovery market size has grown strongly in recent years. It will grow from $6.13 billion in 2023 to $6.47 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to the increasing complexity of drug discovery, demand for efficiency and cost reduction, growing need for high-throughput screening, rising labor costs, and pressure to accelerate drug development timelines. The lab automation in drug discovery market size is expected to see strong growth in the next few years. It will grow to $7.96 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to expanding drug pipelines of pharmaceutical companies, rise in personalized medicine and precision therapeutics, increasing focus on rare diseases and orphan drugs, demand for remote and decentralized clinical trials, the emergence of microfluidics and lab-on-a-chip technologies. Major trends in the forecast period include proliferation of modular and customizable automation solutions, adoption of cloud-based platforms for data management and collaboration, growth of automation in emerging markets, rise of virtual drug discovery companies leveraging automation and digital technologies, development of standardized protocols and interoperable systems.

Rising Demand For Precision Medicine Propels The Growth Of Lab Automation In Drug Discovery Market

The increasing demand for precision medicine is expected to propel the growth of lab automation in the drug discovery market going forward. Precision medicine, also known as personalized medicine, is an approach to medical treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. Lab automation accelerates research, improves experimental repeatability, and improves the efficiency of precision medicine and drug discovery procedures, ultimately leading to the creation of more effective medicines and diagnostics suited to individual patients. For instance, in October 2022, according to the Personalized Medicine Coalition (PMC), a US-based organization that promotes understanding and adoption of personalized medicine, more than 75,000 genetic testing products and 300 personalized medicines will be on the market for people with multiple types of cancer, genetic rare diseases, and a range of chronic and infectious diseases. Therefore, the increasing demand for precision medicine is driving the growth of lab automation in the drug discovery market. Major companies operating in the lab automation in drug discovery market are Thermo Fisher Scientific Inc., Abbott Diagnostics, Roche Holdings Inc., Beckman Coulter, Siemens Healthineers, Becton Dickinson and Company, Agilent Technologies Inc., PerkinElmer Inc., Endress+Hauser, Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., QIAGEN, Beckhoff Automation GmbH & Co. KG, Eppendorf AG, Tecan Group Ltd., Brooks Automation Inc., Hamilton Company, AbCellera Biologics Inc., Hudson Robotics Inc., OpenTrons Labworks Inc., Quanterix Corporation, The Technology Partnership, HighRes Biosolutions Inc., Biosero Inc., Peak Analysis and Automation Ltd., Aurora Biomed Inc., Arctoris, Inveox GmbH, Synthace, Synchron Lab Automation

The Role Of Lab Automation Technologies In Precision Medicine

Major companies operating in lab automation in the drug discovery market are increasing their focus on developing advanced solutions, such as rapid idea-to-data solutions, to gain a competitive edge in the market. A rapid idea-to-data solution refers to a streamlined process or platform that allows individuals or organizations to quickly transform their ideas or concepts into actionable insights or data-driven results. For instance, in April 2022, Strateos Inc., a US-based biotechnology company, launched a rapid idea-to-data solution for small molecule discovery on its cloud lab automation-as-a-service platform. It is a lab automation tool specifically designed for small-molecule discovery in drug development. The on-demand, scalable Strateos Cloud Lab Automation-as-a-Service Platform includes linked robotic automation with 23 workcells and hundreds of instruments. The platform facilitates early lead generation through lead optimization choreographed by a software architecture that allows users to design compounds of interest in the cloud and have them automatically assembled and tested using a variety of methods such as cell-based, biochemical, and structured-activity relationship (SAR) assessments.

Brooks Automation Acquires Aim Lab Automation Technologies Pty Ltd. To Expand Its Market Presence

In March 2023, Brooks Automation, a US-based automation solution company, acquired Aim Lab Automation Technologies Pty Ltd. for an undisclosed amount. With this acquisition, Brooks' lab automation aims to expand its market presence into clinical diagnostics and drive technological advancements, significantly impacting lab automation in the drug discovery market. Aim Lab Automation Technologies Pty Ltd. is an Australia-based company that provides robotic automation instrumentation and modules along with automation solutions designed to enhance automation processes in drug discovery labs. North America was the largest region in the lab automation in drug discovery market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lab automation in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lab automation in drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The lab automation in drug discovery market consists of revenues earned by entities by providing services such as compound screening, assay development, high-throughput screening, data analysis, and optimization of drug candidates. The market value includes the value of related goods sold by the service provider or included within the service offering. The lab automation in drug discovery market also includes sales of robotics and automated workstations, screening systems, plate readers, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The lab automation in drug discovery research report is one of a series of new reports from The Business Research Company that provides lab automation in drug discovery market statistics, including the lab automation in drug discovery industry's global market size, regional shares, competitors with lab automation in drug discovery market share, detailed lab automation in drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the lab automation in drug discovery industry. This lab automation in drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Synthetic Hormones Market Definition And Segments

Synthetic hormones are artificially produced substances that mimic the function of natural hormones in the body. These hormones are typically created through chemical synthesis rather than being derived from natural sources and are used in medical treatments to regulate various physiological processes or to replace hormones that the body may not produce in sufficient quantities. The main types of synthetic hormones are steroid hormones, peptide hormone, amino acid derivatives, and others. Steroid hormones are a class of hormones derived from cholesterol and characterized by their structure, which includes four interconnected carbon rings. Various routes of administration involve oral, nasal, topical, and intravenous administration. Various applications include growth hormone deficiency, thyroid hormone deficiency, menopause, male hypogonadism, and others, and are used by various end users such as hospital pharmacies, retail pharmacies, and online pharmacies. The synthetic hormones market covered in this report is segmented – 1) By Product Type: Steroid Hormones, Peptide Hormone, Amino Acid Derivatives, Other Product Types 2) By Route of Administration: Oral, Nasal, Topical, Intravenous 3) By Application: Growth Hormone Deficiency, Thyroid Hormone Deficiency, Menopause, Male Hypogonadism, Other Applications 4) By End User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The synthetic hormones market size has grown strongly in recent years. It will grow from $6.0 billion in 2023 to $6.38 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to animal growth promotion, performance enhancement, environmental impact, fertility treatments and menopausal symptom management. The synthetic hormones market size is expected to see strong growth in the next few years. It will grow to $7.79 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to expansion of the transgender healthcare market, growing healthcare expenditure and insurance coverage, regulatory approvals, and expanding applications of synthetic hormones. Major trends in the forecast period include rise of plant-based hormone therapy, integration of hormone therapy in anti-aging treatments, technological advancements in drug delivery, and focus on hormone-free birth control.

Rising Incidence Of Hormonal Imbalances Fuels Growth In The Synthetic Hormone Market

The increasing incidence of hormonal imbalances is expected to propel the growth of the synthetic hormones market going forward. A hormonal imbalance refers to having too much or too little of a hormone in the blood, which can occur due to stress, aging, medical conditions, or lifestyle choices, disrupting the average production and regulation of hormones in the body. Synthetic hormones are used to supplement or replace natural hormones in hormonal imbalances, helping regulate bodily functions and alleviate symptoms associated with deficiencies or excesses. For instance, according to the NHS Business Services Authority, a UK-based non-departmental public body, in 2022, around 7.80 million hormone replacement therapy (HRT) items were prescribed in England, marking a 35.0% increase from the previous year. Therefore, the increasing incidence of hormonal imbalances is driving the growth of the synthetic hormones market. Major companies operating in the synthetic hormones market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol Myers Squibb Company, Sanofi SA, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Ferring B.V., Endo Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., IBSA Institute Biochimique SA, American Regent Inc., McGuff Pharmaceuticals Inc., Anhui Anke Biotechnology Co.Ltd., Lyndra Therapeutics Inc., Acerus Pharmaceuticals Corporation, Arch BioPartners Inc., Slayback Pharma LLC

Development Of Long-Acting Recombinant Human Growth Hormone Products Enhances Market Profitability

Major companies operating in the synthetic hormone market are focused on developing innovative products, such as recombinant human growth hormone, to increase their profitability in the market. Recombinant human growth hormone is a synthetic hormone used to treat growth hormone deficiency in children and adults, as well as certain medical conditions associated with growth hormone deficiency. For instance, in February 2022, Pfizer Inc., a US-based pharmaceutical company, and OPKO Health Inc., a US-based medical test and medication company, received marketing authorization for once-weekly NGENLA (somatrogon) injections in the European Union. These injections are intended to treat pediatric growth hormone deficiency in children and adolescents at least three years old. This new long-acting injection provides an alternative for individuals with growth disturbances caused by insufficient growth hormone secretion. NGENLA is administered subcutaneously and lasts longer in the body than daily growth hormone injections, making it possible to help it once a week.

Aspen Pharmacare Expands Presence In China Through Acquisition Of Sandoz's Chinese Business

In November 2023, Aspen Pharmacare Holdings Limited, a South Africa-based pharmaceutical company, acquired Sandoz's Chinese business for $100 million. This acquisition includes Sandoz's China business, which includes products such as the synthetic hormone injectable Sandostatin. This strategic move allows Aspen to expand its footprint and capabilities in China's pharmaceutical market. Sandoz (China) Pharmaceutical Co., Ltd. is a China-based pharmaceutical company that provides a range of pharmaceutical products, including synthetic hormones. North America was the largest region in the synthetic hormones market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the synthetic hormones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the synthetic hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The synthetic hormones market consists of sales of anabolic steroids, insulin, oral contraceptives, and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The synthetic hormones market research report is one of a series of new reports from The Business Research Company that provides synthetic hormones market statistics, including synthetic hormones industry global market size, regional shares, competitors with a synthetic hormones market share, detailed synthetic hormones market segments, market trends and opportunities, and any further data you may need to thrive in the synthetic hormones industry. This synthetic hormones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.